No, CRISPR Hasn't Cured Down Syndrome. Here's What the Viral Study Really Showed
A post going around social media says that Japanese scientists have used CRISPR to remove the extra chromosome that causes Down syndrome, and that "gene editing now targets" the chromosome in babies. It has been shared widely this month, often with a "BREAKING" banner.
The study behind it is real and genuinely interesting. But it is not new, it was not done in babies or in any person, and it is not a treatment. Here is what the researchers actually did, and what it does and does not mean.
Myth vs. fact at a glance
Myth: Scientists can now remove the extra chromosome from babies with Down syndrome. Fact: The work was done only in cells grown in a lab dish.
Myth: This is breaking news. Fact: The paper was published in PNAS Nexus on February 19, 2025, and first went viral in mid-2025.
Myth: These are the first scientists to take the extra chromosome out of human cells. Fact: Earlier lab studies, starting in 2012 and 2013, had already removed or silenced the extra chromosome 21 in cultured cells. What was new here was a CRISPR approach that targets one specific copy.
Myth: A treatment is on the way. Fact: The lead researcher called it a proof-of-concept study. There is no method to deliver it to the trillions of cells in a person.
What causes Down syndrome
Most people have two copies of each chromosome, one from each parent. In Down syndrome, cells carry a third copy of chromosome 21, a condition called trisomy 21. The extra copy raises the activity of hundreds of genes on that chromosome, which affects development of the brain, heart and other organs.
In the United States, about 5,700 babies are born with Down syndrome each year, about 1 in every 640 births, according to the CDC. People with Down syndrome are living longer than ever, and many face a higher risk of certain conditions as they age, including early-onset Alzheimer's disease, which is linked to a gene on chromosome 21.
What the Mie University team did
The study was led by Dr. Ryotaro Hashizume at Mie University Graduate School of Medicine in Japan. The challenge was this: all three copies of chromosome 21 look almost the same, so cutting "the extra one" without touching the other two is difficult.
The team used allele-specific guides. Each person inherits slightly different DNA letters from each parent, so the three copies of chromosome 21 carry small differences. The researchers designed CRISPR-Cas9 guides that match sequences found only on one copy. Cas9 then cut that copy in several places at once, which makes it far more likely that the cell loses the whole chromosome rather than repairing it. If you are new to how CRISPR finds and cuts a specific DNA sequence, my book The Life-Changing Power of Gene Therapy walks through the basics.
They tested the method in two types of lab-grown cells from people with Down syndrome:
Induced pluripotent stem cells, which divide and can become many cell types
Skin fibroblasts, mature cells that had stopped dividing
What the results showed
The extra chromosome was removed in up to 37.5% of treated cells, according to Mie University.
When the team temporarily switched off two DNA repair proteins (DNA ligase IV and polymerase theta), removal became more efficient, because cut chromosomes were less likely to be stitched back together.
In cells that lost the extra copy, gene activity, growth rate and antioxidant capacity shifted back toward the patterns seen in cells with two copies.
The method also worked in fibroblasts that were no longer dividing, which matters because most cells in the adult brain do not divide.
Why this is far from a treatment
The study is a careful step in basic research, but several large problems stand in the way of any medical use:
Not every cell responds. Even at its best, most treated cells kept their extra chromosome. A treatment would need to reach a meaningful share of cells in a living person.
Cutting DNA carries risk. CRISPR can also cut at unintended sites, and the paper reported some of these off-target effects. Making several cuts on a chromosome raises the chance of damage elsewhere in the genome.
The repair-blocking step is not practical. Switching off DNA repair helped in a dish, but doing that in a person could harm healthy cells.
Delivery is unsolved. There is currently no way to send these tools into the trillions of cells of a human body.
Dr. Hashizume has said the paper "solely holds significance as a proof-of-concept study," and that using the method in pregnancy "would not be appropriate." He has described a possible long-term goal of treating specific tissues, such as the brain in adults, to lower the risk of complications like Alzheimer's disease.
The ethical questions
Down syndrome is a lifelong condition, not a disease that people with it necessarily want removed. Many people with Down syndrome and their families see it as part of who they are. Any future research aimed at specific complications, such as heart, blood or brain problems, would need to involve the Down syndrome community and respect personal choice. Writers at Stanford Law School, among others, have discussed how studies like this one can shape public attitudes toward disability.
The bottom line
Researchers at Mie University showed in 2025 that CRISPR can remove one specific copy of chromosome 21 from lab-grown cells, with gene activity and cell growth moving back toward typical patterns. That is a useful scientific tool for studying Down syndrome. It is not a cure, it has not been tried in people, and it is not breaking news. When a science headline sounds too big to be true, the original paper is usually more careful than the post that shares it.
Watch the 30-second Myth vs Fact Short:
Keep exploring with Gene Tech Times
Free guide: subscribe to the Gene Tech Times Briefing on our homepage and get Every FDA-Approved Gene Therapy at a Glance in your inbox.
Watch: 30-second gene therapy Shorts on Gene Tech Times Academy.
Read: The Cheat Codes of Our Genes, real stories of mutations that make some people immune to disease.
New to gene therapy? Start with The Life-Changing Power of Gene Therapy.
As an Amazon Associate, Gene Tech Times earns from qualifying purchases.
— T.N., Gene Tech Times
Comments